AR020190A1 - Composiciones relacionadas con estearoil-coa desaturasa humana y metodos para tratar desordenes de la piel - Google Patents
Composiciones relacionadas con estearoil-coa desaturasa humana y metodos para tratar desordenes de la pielInfo
- Publication number
- AR020190A1 AR020190A1 ARP990104075A ARP990104075A AR020190A1 AR 020190 A1 AR020190 A1 AR 020190A1 AR P990104075 A ARP990104075 A AR P990104075A AR P990104075 A ARP990104075 A AR P990104075A AR 020190 A1 AR020190 A1 AR 020190A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- provides
- stearoyl
- coa desaturase
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9652098P | 1998-08-14 | 1998-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR020190A1 true AR020190A1 (es) | 2002-05-02 |
Family
ID=22257742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990104075A AR020190A1 (es) | 1998-08-14 | 1999-08-13 | Composiciones relacionadas con estearoil-coa desaturasa humana y metodos para tratar desordenes de la piel |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR020190A1 (fr) |
| AU (1) | AU5774699A (fr) |
| CO (1) | CO5280032A1 (fr) |
| WO (1) | WO2000009754A2 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19955349A1 (de) * | 1999-11-17 | 2001-08-02 | Switch Biotech Ag | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen |
| AU4722801A (en) | 2000-02-24 | 2001-09-03 | Xenon Genetics Inc | Methods and compositions using stearoyl-CoA desaturase to identify triglyceride reducing therapeutic agents |
| US6686185B1 (en) * | 2000-03-07 | 2004-02-03 | Millennium Pharmaceuticals, Inc. | 25934, a novel fatty acid desaturase and uses therefor |
| ATE402262T1 (de) * | 2000-09-26 | 2008-08-15 | Xenon Pharmaceuticals Inc | Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden |
| US20040146872A1 (en) * | 2000-11-17 | 2004-07-29 | Winther Michael David | Fat regulated genes, uses thereof and compounds for modulating same |
| US20050043256A1 (en) | 2001-07-30 | 2005-02-24 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| US7132529B2 (en) * | 2001-07-30 | 2006-11-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of stearoyl-CoA desaturase expression |
| EP1429784A4 (fr) * | 2001-08-29 | 2005-09-14 | Xenon Genetics Inc | Essais de criblage a haut rendement mettant en oeuvre des enzymes synthetiques d'acide gras |
| US20030215849A1 (en) * | 2002-03-01 | 2003-11-20 | Marcia Belvin | PDPK1s as modifiers of the p53 pathway and methods of use |
| AU2003294446A1 (en) * | 2002-11-21 | 2004-06-18 | Bayer Pharmaceuticals Corporation | Regulation of stearoyl-coa desaturase to treat obesity |
| FR2853910B1 (fr) * | 2003-04-16 | 2007-08-24 | Galderma Res & Dev | Genes du psoriasis |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| CA2793423C (fr) | 2010-06-11 | 2015-09-15 | Avon Products, Inc. | Utilisation de eclipta prostrata et d'autres inhibiteurs ppar-gamma dans des produits cosmetiques et des compositions correspondantes |
| US20140154206A1 (en) | 2011-05-19 | 2014-06-05 | Toray Industries, Inc. | Immunity induction agent |
| CN108699589B (zh) * | 2016-07-08 | 2021-08-13 | 花王株式会社 | 核酸样品的制备方法 |
| CN115279901A (zh) * | 2020-03-11 | 2022-11-01 | 花王株式会社 | 来自皮肤表面脂质的rna的制备方法 |
-
1999
- 1999-08-12 AU AU57746/99A patent/AU5774699A/en not_active Abandoned
- 1999-08-12 WO PCT/US1999/018387 patent/WO2000009754A2/fr not_active Application Discontinuation
- 1999-08-13 AR ARP990104075A patent/AR020190A1/es unknown
- 1999-08-17 CO CO99051951A patent/CO5280032A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU5774699A (en) | 2000-03-06 |
| WO2000009754A3 (fr) | 2000-08-24 |
| CO5280032A1 (es) | 2003-05-30 |
| WO2000009754A2 (fr) | 2000-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR020190A1 (es) | Composiciones relacionadas con estearoil-coa desaturasa humana y metodos para tratar desordenes de la piel | |
| El‐Mofty et al. | Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study | |
| ATE501722T1 (de) | Therapeutische behandlung androgenrezeptorbedingter leiden | |
| DE69922933D1 (de) | Anwendungen für humane nicht autologe, mesenchymale stammzellen | |
| ATE280590T1 (de) | Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen | |
| MXPA02001099A (es) | Compuestos para modular el receptor rage. | |
| DK1053313T3 (da) | Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser | |
| CY1107715T1 (el) | Διαγνωση και αγωγη του καρκινου του προστατη | |
| NZ507308A (en) | Materials and methods for gene therapy | |
| Hyatt et al. | PAX3/7 expression coincides with MyoD during chronic skeletal muscle overload | |
| WO1998048027A3 (fr) | Produits agissant contre des affections retiniennes et traitement correspondant | |
| DE502004008793D1 (fr) | ||
| ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
| ES2114615T3 (es) | Nueva sonda para el diagnostico de tumores o la terapia de tumores. | |
| MXPA03011270A (es) | Uso de antagonistas rank para tratar cancer. | |
| Benmaamar et al. | Induced down‐regulation of neuropeptide Y‐Y1 receptors delays initiation of kindling | |
| BRPI0508053A (pt) | método de combater toxicidade causada por um composto antifolato, e de tratar uma doença, usos de enzima que possui atividade de carbóxi-peptidase g, de composto antifolato, de agente de resgate de rota de folato, e de enzima que possui atividade de carbóxi-peptidase g e de um agente de resgate de rota de folato, sistema terapêutico, e, método ex vivo de clivar um grupo l-glutamato terminal de um composto, de determinar a taxa e/ou extenção de clivagem de um composto, e de clivagem de um composto | |
| MXPA03008210A (es) | Produccion de altos niveles del factor ix transgenico sin rescate del gen, y sus usos terapeuticos. | |
| Saito et al. | Differential expression of the alternatively spliced forms of prosaposin mRNAs in rat choroid plexus | |
| EA200401390A1 (ru) | N-ацетилглюкозамин-6-фосфатдеацетилаза человека, взаимодействующая с каспазой-8, и способы ее применения | |
| EA200700346A1 (ru) | Бактериофаг- и профаг-специфические протеины в генной терапии рака | |
| FR2786100B1 (fr) | Nouvelle application therapeutique de la nicergoline | |
| ATE239749T1 (de) | Phosphor-enthaltende dendrimere als transfektionsagente | |
| BRPI0416507A (pt) | polipeptìdeo, molécula de ácido nucleico purificada, vetor, célula hospedeira, uso de um polipeptìdeo, uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira, composição farmacêutica, uso de um antagonista de citocina ou um agente anti-inflamatório, uso de polipeptìdeo,uma molécula de ácido nucleico, um vetor, ou uma célula hospedeira,e um antagonista de citocina ou um agente anti-inflamatório, método de tratamento de uma doença em um paciente, e para a identificação de um composto e, animal transgênico não humano | |
| WO2005039645A3 (fr) | Therapies et agents therapeutiques anticancereux cibles sur les facteurs sp1 et sp3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |